Beijing Konruns Pharmaceutical (603590.SH) Completes First Patient Enrollment in Phase II Clinical Trial of KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Stock News2025-12-15

Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as "KC1036") have successfully completed the first patient enrollment and dosing in the Phase II clinical trial titled "KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KC1036-COM-01)." KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 exhibits antitumor activity by inhibiting multiple targets, including VEGFR2 and AXL. The drug demonstrates strong VEGFR vascular targeting, suppressing tumor cell growth, while AXL inhibition enhances the host's antitumor immune response, thereby preventing tumor immune evasion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1124289200?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-15 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1124289200","market":"hk","top_or_hot":-1,"title":"Beijing Konruns Pharmaceutical (603590.SH) Completes First Patient Enrollment in Phase II Clinical Trial of KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","media":"Stock News","content":"<p>Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as \"KC1036\") have successfully completed the first patient enrollment and dosing in the Phase II clinical trial titled \"KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KC1036-COM-01).\" KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 exhibits antitumor activity by inhibiting multiple targets, including VEGFR2 and AXL. The drug demonstrates strong VEGFR vascular targeting, suppressing tumor cell growth, while AXL inhibition enhances the host's antitumor immune response, thereby preventing tumor immune evasion.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Konruns Pharmaceutical (603590.SH) Completes First Patient Enrollment in Phase II Clinical Trial of KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Konruns Pharmaceutical (603590.SH) Completes First Patient Enrollment in Phase II Clinical Trial of KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-15 20:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as \"KC1036\") have successfully completed the first patient enrollment and dosing in the Phase II clinical trial titled \"KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KC1036-COM-01).\" KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 exhibits antitumor activity by inhibiting multiple targets, including VEGFR2 and AXL. The drug demonstrates strong VEGFR vascular targeting, suppressing tumor cell growth, while AXL inhibition enhances the host's antitumor immune response, thereby preventing tumor immune evasion.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4023","symbol_name":"应用软件","start_time":0,"source_url":"","article_id":"1124289200","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1124289200","pubTimestamp":1765800626,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as \"KC1036\") have successfully completed the first patient enrollment and dosing in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"603590":"康辰药业","BK4023":"应用软件","BK0239":"医药制造","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","PD":"PagerDuty, Inc.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC"},"translate_title":"北京康润斯制药（603590.SH）完成KC1036联合PD-1抗体和铂类化疗治疗晚期复发或转移性食管鳞癌II期临床首例患者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"603590":1,"PD":1},"content_text":"Beijing Konruns Pharmaceutical Co., Ltd. (603590.SH) announced that its self-developed KC1036 tablets (referred to as \"KC1036\") have successfully completed the first patient enrollment and dosing in the Phase II clinical trial titled \"KC1036 Combined with PD-1 Antibody and Platinum-Based Chemotherapy as First-Line Treatment for Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (KC1036-COM-01).\" KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 exhibits antitumor activity by inhibiting multiple targets, including VEGFR2 and AXL. The drug demonstrates strong VEGFR vascular targeting, suppressing tumor cell growth, while AXL inhibition enhances the host's antitumor immune response, thereby preventing tumor immune evasion.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1124289200","isCrawlerRequest":true}